MENLO PARK, Calif. - A Bay Area biotech company is behind a potentially groundbreaking blood test that promises to be a game-changer in cancer detection, with the ability to discover more than 50 types of cancer even before symptoms appear.

Menlo Park-based GRAIL said its multi-cancer early detection (MCED) test, Galleri, can find some of the deadliest cancers that aren’t a part of regular screenings.

Those regular screenings include tests for breast, colorectal, lung and prostate cancers.

But GRAIL officials said there are a host of cancers that aren’t a part of routine evaluations.

"Unfortunately, about 70% of cancer deaths occur due to cancers we're not looking for at all," Dr. Josh Ofman, GRAIL president, explained in a video describing the test’s success.

By the numbers:

T

See Full Page